Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
2.

Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards.

Espinosa-Carrasco J, Pulido TH, Erb I, Dierssen M, Ponomarenko J, Notredame C.

Nucleic Acids Res. 2019 Jul 2;47(W1):W600-W604. doi: 10.1093/nar/gkz414.

3.

Evaluation of Macitentan in Patients With Eisenmenger Syndrome.

Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J, Papadakis K, Pulido T, Galiè N; MAESTRO Study Investigators.

Circulation. 2019 Jan 2;139(1):51-63. doi: 10.1161/CIRCULATIONAHA.118.033575.

4.

Risk stratification and medical therapy of pulmonary arterial hypertension.

Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

5.

Advances in medical therapy for pulmonary arterial hypertension.

Sisniega C, Zayas N, Pulido T.

Curr Opin Cardiol. 2019 Jan;34(1):98-103. doi: 10.1097/HCO.0000000000000583.

PMID:
30394906
6.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

7.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

8.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

9.

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.

Jansa P, Pulido T.

Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. doi: 10.1007/s40256-017-0260-1. Review.

10.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

11.

The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review.

Wen KX, Miliç J, El-Khodor B, Dhana K, Nano J, Pulido T, Kraja B, Zaciragic A, Bramer WM, Troup J, Chowdhury R, Ikram MA, Dehghan A, Muka T, Franco OH.

PLoS One. 2016 Dec 14;11(12):e0167201. doi: 10.1371/journal.pone.0167201. eCollection 2016. Review.

12.

[From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension: Pathobiology and pathophysiology].

Beltrán-Gámez ME, Sandoval-Zárate J, Pulido T.

Arch Cardiol Mex. 2017 Jan - Mar;87(1):26-34. doi: 10.1016/j.acmx.2016.10.003. Epub 2016 Dec 10. Review. Spanish.

PMID:
27956338
13.

Persistent pulmonary hypertension and right ventricular function after percutaneous mechanical thrombectomy in severe acute pulmonary embolism.

Eid-Lidt G, Gaspar J, Sandoval J, Gonzalez-Pacheco H, Arias A, Acevedo P, Pulido T, Martinez-Sanchez C, Martinez-Rios MA.

Eur Respir J. 2017 Jan 11;49(1). pii: 1600910. doi: 10.1183/13993003.00910-2016. Print 2017 Jan. No abstract available.

14.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Erratum in: Chest. 2018 May;153(5):1287.

15.

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM.

Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8.

PMID:
27067478
16.

Medical therapies for pulmonary arterial hypertension.

Pulido T, Zayas N, de Mendieta MA, Plascencia K, Escobar J.

Heart Fail Rev. 2016 May;21(3):273-83. doi: 10.1007/s10741-016-9527-x. Review.

PMID:
26791159
17.

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ.

Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22.

18.

Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.

Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1345-54. doi: 10.1164/rccm.201501-0196OC.

19.

[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].

Beltrán-Gámez ME, Sandoval-Zárate J, Pulido T.

Arch Cardiol Mex. 2015 Jul-Sep;85(3):215-24. doi: 10.1016/j.acmx.2015.03.001. Epub 2015 Jun 2. Review. Spanish.

PMID:
26047999
20.

[Pulmonary arterial hypertension: epidemiology and registries].

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:67-77. Turkish.

21.

Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N.

JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11.

22.

Pulmonary hypertension due to acute respiratory distress syndrome.

Ñamendys-Silva SA, Santos-Martínez LE, Pulido T, Rivero-Sigarroa E, Baltazar-Torres JA, Domínguez-Cherit G, Sandoval J.

Braz J Med Biol Res. 2014 Oct;47(10):904-10. Epub 2014 Aug 8.

23.

STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.

Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD; STARTS-2 Investigators.

Circulation. 2014 May 13;129(19):1914-23. doi: 10.1161/CIRCULATIONAHA.113.005698. Epub 2014 Mar 17.

PMID:
24637559
24.

Differences in right ventricular remodeling secondary to pressure overload in patients with pulmonary hypertension.

Gomez-Arroyo J, Santos-Martinez LE, Aranda A, Pulido T, Beltran M, Muñoz-Castellanos L, Dominguez-Cano E, Sonnino C, Voelkel NF, Sandoval J.

Am J Respir Crit Care Med. 2014 Mar 1;189(5):603-6. doi: 10.1164/rccm.201309-1711LE. No abstract available.

PMID:
24579837
25.

Macitentan and pulmonary arterial hypertension.

Pulido T, Rubin LJ, Simonneau G.

N Engl J Med. 2014 Jan 2;370(1):82-3. doi: 10.1056/NEJMc1313112. No abstract available.

PMID:
24382071
26.

Pulmonary arterial hypertension: epidemiology and registries.

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023. Review.

27.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators.

N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

28.

Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice.

Beghetti M, Berger RM, Schulze-Neick I, Day RW, Pulido T, Feinstein J, Barst RJ, Humpl T; TOPP Registry Investigators.

Eur Respir J. 2013 Sep;42(3):689-700. doi: 10.1183/09031936.00140112. Epub 2013 Apr 5.

29.

Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.

White RJ, Torres F, Allen R, Jerjes C, Pulido T, Yehle D, Howell M, Laliberte K, Marier JF, Tapson VF.

J Cardiovasc Pharmacol. 2013 Jun;61(6):474-81. doi: 10.1097/FJC.0b013e31828685da.

PMID:
23328389
30.

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.

Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ.

Circulation. 2013 Feb 5;127(5):624-33. doi: 10.1161/CIRCULATIONAHA.112.124388. Epub 2013 Jan 10.

PMID:
23307827
31.

Does anticoagulation in Eisenmenger syndrome impact long-term survival?

Sandoval J, Santos LE, Córdova J, Pulido T, Gutiérrez G, Bautista E, Martinez Guerra ML, Peña H, Broberg CS.

Congenit Heart Dis. 2012 May-Jun;7(3):268-76. doi: 10.1111/j.1747-0803.2012.00633.x. Epub 2012 Feb 23.

PMID:
22360787
32.

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL.

Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29.

PMID:
22128226
33.

Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.

Sandoval J, Torbicki A, Souza R, Ramírez A, Kurzyna M, Jardim C, Jerjes-Sánchez Díaz C, Teal SA, Hwang LJ, Pulido T; STRIDE-4 investigators.

Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. doi: 10.1016/j.pupt.2011.10.002. Epub 2011 Nov 2.

PMID:
22079088
34.

The role of pulmonary pressure/cardiac index to identify pulmonary hemodynamic responders to acute oxygen breathing pulmonary hypertension COPD patients.

Lupi-Herrera E, Sandoval J, Efren Santos L, Pulido T, Rosas-Peralta M.

Arch Cardiol Mex. 2011 Jul-Sep;81(3):208-16.

PMID:
21975235
35.

Relative fracture toughness of bis-acryl interim resin materials.

Knobloch LA, Kerby RE, Pulido T, Johnston WM.

J Prosthet Dent. 2011 Aug;106(2):118-25. doi: 10.1016/S0022-3913(11)60106-6.

PMID:
21821166
36.

Left and right ventricular power: outputs are the strongest hemodynamic correlates to allow identification of acute responders to vasodilator treatment in idiopathic pulmonary arterial hypertension.

Lupi-Herrera E, Sandoval J, Figueroa J, Carrillo A, Aguirre R, Santos-Martínez LE, Pulido T.

Arch Cardiol Mex. 2011 Apr-Jun;81(2):100-7.

PMID:
21775243
37.

Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension.

Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, Rodríguez A, Pulido T.

Eur Respir J. 2011 Dec;38(6):1343-8. doi: 10.1183/09031936.00072210. Epub 2011 Feb 24.

38.

[Medical reflections on a case of pulmonary thromboembolism in pregnancy].

Santos-Martínez LE, Murillo C, Rodríguez A, Puente M, Miranda T, Contreras M, Guevara P, Rosado-Bosque C, Rojas G, Pulido T, Sandoval J, Zamora K, Baranda F.

Arch Cardiol Mex. 2010 Oct-Dec;80(4):255-60. Review. Spanish.

PMID:
21169090
39.

[Pressure-flow relationships interpretation in idiopathic pulmonary arterial hypertension].

Lupi-Herrera E, Santos-Martínez LE, Pulido T, Sandoval J.

Arch Cardiol Mex. 2010 Jul-Sep;80(3):163-73. Spanish.

PMID:
21147582
41.

[Capillary blood gas test usefulness to evaluate gas exchange with 21% and 100% of oxygen inspired fractions in subjects with stable cardiopulmonary disease at 2,240 meters above sea level].

Santos-Martínez LE, Martínez-Guerra ML, Duran A, Rodríguez F, Gotés J, Roquet I, López LA, Pulido A, Lupi E, Bautista E, Pulido T, Sandoval J.

Arch Cardiol Mex. 2009 Jan-Mar;79(1):18-26. Spanish.

PMID:
19545070
42.

Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.

Pulido T, Sandoval J, Roquet I, Gutiérrez R, Rueda T, Peña H, Santos E, Miranda MT, Lupi E.

Eur J Clin Invest. 2009 Jun;39 Suppl 2:14-8. doi: 10.1111/j.1365-2362.2009.02116.x. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.

PMID:
19335742
43.

A clinical registry of dementia based on the principle of epidemiological surveillance.

Garre-Olmo J, Flaqué M, Gich J, Pulido TO, Turbau J, Vallmajo N, Viñas M, López-Pousa S; Registry of Dementia of Girona Study Group (ReDeGi Group).

BMC Neurol. 2009 Jan 28;9:5. doi: 10.1186/1471-2377-9-5.

44.

[Impact of the deep breathing maneuver in the gas exchange in the subject with severe obesity and pulmonary arterial hypertension associated to Eisenmenger's syndrome].

Santos-Martínez LE, Martínez-Guerra ML, Bautista E, Castillo F, Castañón A, Pulido T, Hernández JL, Sandoval J.

Arch Cardiol Mex. 2008 Jul-Sep;78(3):265-72. Spanish.

PMID:
18959013
45.

Combined clot fragmentation and aspiration in patients with acute pulmonary embolism.

Eid-Lidt G, Gaspar J, Sandoval J, de los Santos FD, Pulido T, González Pacheco H, Martínez-Sánchez C.

Chest. 2008 Jul;134(1):54-60. doi: 10.1378/chest.07-2656. Epub 2008 Jan 15.

PMID:
18198243
46.

[Massive pulmonary embolism, thrombus in transit, and right ventricular dysfunction].

Santos Martínez LE, Uriona Villarroel JE, Exaire Rodríguez JE, Mendoza D, Martínez Guerra ML, Pulido T, Bautista E, Castañón A, Sandoval J.

Arch Cardiol Mex. 2007 Jan-Mar;77(1):44-53. Spanish.

PMID:
17500192
47.

Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension.

Souza R, Martins BC, Jardim C, Cortopassi F, Fernandes CJ, Pulido T, Sandoval J.

Int J Clin Pract. 2007 Jan;61(1):153-6.

PMID:
17229188
48.

Pulmonary embolism as a cause of death in patients with heart disease: an autopsy study.

Pulido T, Aranda A, Zevallos MA, Bautista E, Martínez-Guerra ML, Santos LE, Sandoval J.

Chest. 2006 May;129(5):1282-7.

PMID:
16685020
49.

[Clinical implications and prognostic significance of the study on the circadian variation of heart rate variability in patients with severe pulmonary hypertension].

Rosas-Peralta M, Sandoval-Zárate J, Attie F, Pulido T, Santos E, Granados NZ, Miranda T, Escobar V.

Gac Med Mex. 2006 Jan-Feb;142(1):19-28. Spanish.

PMID:
16548288
50.

[Modification of a hydraulic device for controlled banding of the trunk of the pulmonary artery in dogs].

Santos Martínez LE, Gotés J, Flores P, Tena C, Graullera V, Pulido T, Bautista E, Infante O, Martínez Guerra ML, Castañón A, Ramírez S, Soule M, Sandoval Zárate J.

Arch Cardiol Mex. 2005 Jul-Sep;75 Suppl 3:S3-10-20. Spanish.

PMID:
16366166

Supplemental Content

Loading ...
Support Center